top of page

Sernova Corp: Pioneering Therapeutic Cell Technologies for Chronic Diseases

Sernova Corp is recognized for its groundbreaking work in the realm of biotechnology. Currently, this clinical-stage company is making waves with its innovative cell therapies to combat chronic illnesses. Some of these include insulin-dependent diabetes, thyroid disease, and distinct blood disorders, such as hemophilia A. Sernova's Revolutionary Approach Sernova's primary focus revolves around creating a 'functional cure' for insulin-dependent diabetes. The cornerstone of this initiative is the Cell Pouch System, an implantable and scalable medical device, which is designed to house immune-protected therapeutic cells. On implantation, the Cell Pouch forms a natural, vascularized tissue environment within the patient's body. This environment facilitates the long-term survival and function of the implanted cells. These cells release crucial factors that are often absent or deficient in patients with chronic diseases. In an ongoing Phase 1/2 clinical trial at the University of Chicago, Sernova's Cell Pouch System has shown promising results in potentially providing a 'functional cure' for T1D patients. Defending Therapeutic Cells Sernova is also working on a proprietary project in association with the University of Miami. This initiative aims to safeguard therapeutic cells from the attacks of the immune system, thereby eliminating the need for chronic, systemic immunosuppression. Strategic Partnership with Evotec In May 2022, Sernova and Evotec forged a global strategic alliance to develop an implantable off-the-shelf iPSC (induced pluripotent stem cells) based islet replacement therapy. This partnership is expected to provide Sernova with an essentially unlimited supply of insulin-producing cells. This availability could pave the way for treating millions of patients suffering from insulin-dependent diabetes (both type 1 and type 2). Additional Development Programs Sernova is also progressing two other development programs that utilize its Cell Pouch System. One of these involves a cell therapy for hypothyroid disease that occurs as a result of thyroid gland removal. The other program is working towards an ex vivo lentiviral Factor VIII gene therapy for hemophilia A. Conclusion Sernova continues to push the boundaries of medical technology to improve the lives of those suffering from chronic diseases. Their innovative approaches and strategic partnerships hold great promise for the future of biotechnology. Disclaimer: The information presented in this article has been gathered from various sources. If there are any inaccuracies, please contact us for modifications. References:


Recent Posts

See All

Biogen's Acquisition of Reata Pharmaceuticals

Introduction In a significant development for the medical community, Biogen Inc. (Nasdaq: BIIB) has announced its definitive agreement to acquire Reata Pharmaceuticals, Inc. (Nasdaq: RETA). This strat


bottom of page